Alvotech Reiterates Meeting US Humira Biosimilar Launch Date
As Partner Cipla Bags Australian Approval For AVT02 Adalimumab Asset
Executive Summary
Recently public Alvotech had much to share as part of its nine-month financial report, including updates on adalimumab in the US and the process to begin biosimilar golimumab trials.
You may also be interested in...
FDA Promises Interchangeability For Alvotech’s 100mg/ml Humira Rival – If It Passes Inspection
Alvotech has been bolstered by a US FDA confirmation that its AVT02 adalimumab candidate can be approved as an interchangeable biosimilar based on the data provided in its filing – but first, the Icelandic firm must pass an upcoming facility inspection.
Alvotech Targets MENA In Multi-Biosimilar Commercialization Deal
Three firms across Europe and North Africa sign to sell Alvotech biosimilar candidates in 19 MENA countries as the Icelandic developer shifts focus from R&D to global commercialization.
What’s Next? Five Things To Look Out For In December
In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.